Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  László, Andrea ^a   Kalabay, László ^a   Nemcsik, János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Creatine kinase; Exercise; Metabolic syndrome; Myopathy; Statin fibrate combination therapy

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; EXERCISE; HUMAN; MALE; METABOLIC SYNDROME X; MYOSITIS;

ADULT; EXERCISE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MYOSITIS;

MLCS; MLOWN;

EID: 84873249294     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-52     Document Type: Article

References (37)

1. The metabolic syndrome-a new worldwide definition. Alberti KG, Zimmer P, Shaw J, IDF Epidemiology Task Force Consensus Group, Lancet 2005 366 9491 1059 62 10.1016/S0140-6736(05)67402-8 16182882 (Pubitemid 41338752)
2. Health benefits of physical activity: the evidence. Warburton DE, Nicol CW, Bredin SS, Cmaj 2006 174 6 801 809 16534088
3. Effects of the amount and intensity of exercise on plasma lipoproteins. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, et al. N Engl J Med 2002 347 19 1483 1492 10.1056/NEJMoa020194 12421890 (Pubitemid 35257587)
4. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, et al. Eur Hear J 2011 32 14 1769 1818
5. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ, Curr Med Res Opin 2007 23 3 553 563 10.1185/030079906X167660 17357251 (Pubitemid 46456903)
6. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). de Sauvage Nolting PR, Buirma RJ, Hutten BA, Kastelein JJ, Am J Cardiol 2002 90 2 181 184 10.1016/S0002-9149(02)02449-9 12106856 (Pubitemid 34775134)
7. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G, Cardiovasc Drugs Ther 2003 17 5-6 459 465 15107601 (Pubitemid 38339916)
8. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM, Circulation 2006 114 25 2788 2797 10.1161/CIRCULATIONAHA.106. 624890 17159064 (Pubitemid 46018281)
9. Potential adverse effects of statins on muscle. Tomlinson SS, Mangione KK, Phys Ther 2005 85 5 459 465 15842193 (Pubitemid 40586829)
10. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Sniderman AD, Am J Cardiol 2004 94 9A 30F 34F 15519289 (Pubitemid 39425216)
11. Molecular basis of statin-associated myopathy. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD, Atherosclerosis 2009 202 1 18 28 10.1016/j.atherosclerosis.2008.05.021 18585718
12. Statin-induced apoptosis and skeletal myopathy. Dirks AJ, Jones KM, Am J Physiol 2006 291 6 1208 1212 10.1152/ajpcell.00226.2006 (Pubitemid 44878591)
13. HMG-CoA reductase inhibitors and myotoxicity. Ucar M, Mjorndal T, Dahlqvist R, Drug Saf 2000 22 6 441 457 10.2165/00002018-200022060-00003 10877038 (Pubitemid 30386462)
14. FDA adverse event reports on statin-associated rhabdomyolysis. Omar MA, Wilson JP, Ann Pharmacother 2002 36 2 288 295 11847951 (Pubitemid 34126824)
15. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B, Cardiovasc Drugs Ther 2005 19 6 403 414 10.1007/s10557-005-5686-z 16453090 (Pubitemid 43228152)
16. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J, Am J Cardiol 2005 95 4 462 468 10.1016/j.amjcard. 2004.10.012 15695129 (Pubitemid 40247539)
17. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH, Am J Cardiovasc Drugs 2010 10 3 175 186 10.2165/11533430-000000000-00000 20524719
18. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE, J Clin Epidemiol 2007 60 8 812 818 10.1016/j.jclinepi. 2006.11.006 17606177 (Pubitemid 47007672)
19. Cerivastatin and gemfibrozil-associated rhabdomyolysis. Bruno-Joyce J, Dugas JM, MacCausland OE, Ann Pharmacother 2001 35 9 1016 1019 11573847
20. Statin myotoxicity is associated with changes in the cardiopulmonary function. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH, Atherosclerosis 2004 177 1 183 188 10.1016/j.atherosclerosis.2004.06.014 15488882 (Pubitemid 39361154)
21. Safety considerations with fibrate therapy. Davidson MH, Armani A, McKenney JM, Jacobson TA, Am J Cardiol 2007 99 6A 3C 18C 17368275
22. Physical activity in statin-treated patients. Mascitelli L, Pezzetta F, Int J Cardiol 2009 134 1 136 137 10.1016/j.ijcard.2007.12.048 18372066
23. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Sinzinger H, O'Grady J, Br J Clin Pharmacol 2004 57 4 525 528 10.1111/j.1365-2125.2003.02044. x 15025753 (Pubitemid 38519660)
24. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. Eur J Cardiovasc Prev Rehabil 2007 14 2 1 40 10.1097/01.hjr.0000277984.31558.c4 17726406 (Pubitemid 47342420)
25. Means and ends of statins and low-density lipoprotein cholesterol lowering. LaRosa JC, J Am Coll Cardiol 2007 50 5 419 420 10.1016/j.jacc.2007.04. 044 17662393 (Pubitemid 47088129)
26. Primary prevention of coronary artery disease. Domanski MJ, N Engl J Med 2007 357 15 1543 1545 10.1056/NEJMe078183 17928603 (Pubitemid 47572643)
27. Statins for primary prevention of coronary artery disease. Mascitelli L, Pezzetta F, Lancet 2007 369 9567 1078 1079 author reply 1079 17398299 (Pubitemid 46505163)
28. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Jones PH, Davidson MH, Am J Cardiol 2005 95 1 120 122 10.1016/j.amjcard.2004.08.076 15619408 (Pubitemid 40051126)
29. Lovastatin increases exercise-induced skeletal muscle injury. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR, Metab Clin Exp 1997 46 10 1206 1210 10.1016/S0026-0495(97)90218-3 9322808 (Pubitemid 27418513)
30. Creatine kinase monitoring in sport medicine. Brancaccio P, Maffulli N, Limongelli FM, Br Med Bull 2007 81-82 209 230 23184854 (Pubitemid 351194486)
31. Serum creatine kinase levels and renal function measures in exertional muscle damage. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD, Med Sci Sports Exerc 2006 38 4 623 627 10.1249/01.mss.0000210192.49210.fc 16679975
32. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O'Fallon KS, Gadarla M, Thompson PD, Atherosclerosis 2008 200 1 121 125 10.1016/j.atherosclerosis.2007.12.029 18261731
33. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW, Drug Metab Dispos 2006 34 1 121 30 16221753 (Pubitemid 43042653)
34. Pharmacokinetic interactions between statins and fibrates. Corsini A, Bellosta S, Davidson MH, Am J Cardiol 2005 96 9A 44K 49K discussion 34K-35K 16291014 (Pubitemid 41598112)
35. Clinical pharmacokinetics of nebivolol. A review. Van Peer ASE, Woestenborghs R, Drug Invest 1991 3 Suppl. 1 25 30
36. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ, Pharmacogenet Genomics 2007 17 9 695 707 10.1097/FPC.0b013e328012d0a9 17700359 (Pubitemid 47263065)
37. An assessment of statin safety by muscle experts